AbbVie Inc. (ABBV)

77.30
0.84 1.10
NYSE : Health Technology
Prev Close 76.46
Open 76.88
Day Low/High 75.85 / 77.85
52 Wk Low/High 62.66 / 94.98
Volume 7.85M
Avg Volume 8.51M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 111.09B
EPS 3.70
P/E Ratio 26.74
Div & Yield 4.28 (5.60%)
Another Day, Another Deal: What to Watch from AbbVie, Allergan, Micron, Buffett

Another Day, Another Deal: What to Watch from AbbVie, Allergan, Micron, Buffett

Wall Street woke up to another major deal. Here's what to watch from AbbVie's acquistion of Allergan, Warren Buffett's Kraft comments and Micron earnings after the bell.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

AbbVie Is Likely to Decline as Investors Digest Its Takeover Announcement

AbbVie Is Likely to Decline as Investors Digest Its Takeover Announcement

Let's look closer at the charts and indicators of ABBV.

Dow Futures Flat, Dollar Sips as Trade Concerns Trim Risk Appetite Ahead of G20

Dow Futures Flat, Dollar Sips as Trade Concerns Trim Risk Appetite Ahead of G20

U.S. equity futures drifted lower Tuesday, setting up the S&P 500 for its first three-day decline since early May, as investors peel back from recent record highs and take a defensive stance on risk ahead of this weekend's G20 Summit in Japan.

AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles

AbbVie Fizzles, Gold, Bitcoin and (Some) Biotech Sizzles

AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.

Micron, FedEx, Trump-Xi, Tesla and Amazon - 5 Things You Must Know

Micron, FedEx, Trump-Xi, Tesla and Amazon - 5 Things You Must Know

U.S. stock futures decline as investors take a defensive stance on risk ahead of this weekend's G-20 summit in Japan; Micron reports earnings Tuesday; FedEx, which also reports earnings, sues the U.S. government arguing new trade regulations put an 'impossible burden' on the company to monitor its shipments.

AbbVie To Acquire Allergan In Transformative Move For Both Companies

AbbVie To Acquire Allergan In Transformative Move For Both Companies

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

AbbVie Announces US FDA Lifts Partial Clinical Hold On Phase 3 Study Of Venetoclax In Patients With Multiple Myeloma Positive For The T(11;14) Genetic Abnormality

AbbVie Announces US FDA Lifts Partial Clinical Hold On Phase 3 Study Of Venetoclax In Patients With Multiple Myeloma Positive For The T(11;14) Genetic Abnormality

- FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., June 20, 2019 /PRNewswire/ -- The board of directors of AbbVie Inc.

Fed Up, Yet?

The narrative in the market is that we are waiting for the Fed decision on Wednesday -- but of course it's not that clear cut is it?

New Long-Term Data From Upadacitinib Phase 3 Studies In Rheumatoid Arthritis Including Results On Clinical Remission At 48 Weeks Presented At EULAR

New Long-Term Data From Upadacitinib Phase 3 Studies In Rheumatoid Arthritis Including Results On Clinical Remission At 48 Weeks Presented At EULAR

- Data from SELECT-EARLY and SELECT-COMPARE show a significantly higher proportion of patients treated with upadacitinib monotherapy or in combination with methotrexate (MTX) maintaining clinical remission compared with MTX or adalimumab plus MTX, respectively, at 48 weeks1,2

New Two-Year Data At The 24th World Congress Of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance

New Two-Year Data At The 24th World Congress Of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance

- Longer-term results from IMMhance showed 73 percent and 72 percent of patients treated with continuous SKYRIZI™ (risankizumab) experienced complete skin clearance (defined as sPGA 0 and PASI 100, respectively) at week 94, among patients who achieved sPGA 0/1 at week 28 [1]

AbbVie To Present At The Goldman Sachs Global Healthcare Conference

AbbVie To Present At The Goldman Sachs Global Healthcare Conference

NORTH CHICAGO, Ill., June 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 40 th Annual Global Healthcare Conference on Wednesday, June 12, 2019.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

AbbVie Presents Data From Venetoclax Chemotherapy-Free Combination Regimen For Patients With Previously Untreated Chronic Lymphocytic Leukemia

AbbVie Presents Data From Venetoclax Chemotherapy-Free Combination Regimen For Patients With Previously Untreated Chronic Lymphocytic Leukemia

-  Phase 3 data from CLL14 study were highlighted in an oral presentation (abstract #7502) today at ASCO and published in the New England Journal of Medicine -  Patients treated with venetoclax plus obinutuzumab lived significantly longer without their...

AbbVie Presents Results From Several Studies And Clinical Trials Investigating Medicines Across More Than 15 Cancers At The 2019 ASCO And EHA Meetings

AbbVie Presents Results From Several Studies And Clinical Trials Investigating Medicines Across More Than 15 Cancers At The 2019 ASCO And EHA Meetings

- AbbVie to present more than 40 abstracts from its oncology pipeline at this year's ASCO and EHA medical meetings in June

Going in Circles

We can't get a break under all those round numbers on the major indexes, yet, the Russell 2000 outperforms and the number of stocks making new lows mostly stays put.

Gilead Sciences Slips on Goldman's Downgrade to Sell

Gilead Sciences Slips on Goldman's Downgrade to Sell

Shares of Gilead Sciences fall after Goldman Sachs downgrades the stock to sell from neutral.

AbbVie Provides Update On Depatuxizumab Mafodotin (Depatux-M), An Investigational Medicine For Newly Diagnosed Glioblastoma, An Aggressive Form Of Brain Cancer

AbbVie Provides Update On Depatuxizumab Mafodotin (Depatux-M), An Investigational Medicine For Newly Diagnosed Glioblastoma, An Aggressive Form Of Brain Cancer

-Phase 3 INTELLANCE-1 study, conducted in collaboration with the RTOG Foundation, did not meet primary endpoint of overall survival at the interim analysis and demonstrated no survival benefit for patients receiving Depatux-M

Aurora Cannabis Up 2.4%; Tera Tech Off 5.6%: Cannabis Stocks Mixed

Aurora Cannabis Up 2.4%; Tera Tech Off 5.6%: Cannabis Stocks Mixed

Gainers trail losers in Cannabis sector action Thursday.

MC10, Inc. And AbbVie (NYSE:ABBV) Announce Clinical Trials In Multiple Sclerosis Using The BioStamp NPoint® System

MC10, Inc. And AbbVie (NYSE:ABBV) Announce Clinical Trials In Multiple Sclerosis Using The BioStamp NPoint® System

MC10, Inc., a healthcare technology company specializing in wearable digital health sensors, and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the companies are working together on clinical trials designed to...

AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation With Boehringer Ingelheim

AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation With Boehringer Ingelheim

NORTH CHICAGO, Ill., May 14, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that it has resolved U.

AbbVie To Present At The UBS Global Healthcare Conference

AbbVie To Present At The UBS Global Healthcare Conference

NORTH CHICAGO, Ill., May 14, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 21, 2019.

AbbVie To Present At The Bank Of America Merrill Lynch Healthcare Conference

AbbVie To Present At The Bank Of America Merrill Lynch Healthcare Conference

NORTH CHICAGO, Ill., May 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019.

European Commission Approves SKYRIZI™ (risankizumab) For The Treatment Of Moderate To Severe Plaque Psoriasis

European Commission Approves SKYRIZI™ (risankizumab) For The Treatment Of Moderate To Severe Plaque Psoriasis

- Approval based on results from clinical studies showing high rates of skin clearance at 16 weeks; this clearance was durable at one year with every 12-week dosing[1-4]

AbbVie To Present New And Updated Data Of Investigational Medicines For Parkinson's Disease And Multiple Sclerosis At 2019 American Academy Of Neurology Annual Meeting

AbbVie To Present New And Updated Data Of Investigational Medicines For Parkinson's Disease And Multiple Sclerosis At 2019 American Academy Of Neurology Annual Meeting

- Presentations include updates on ABBV-951, a subcutaneous infusion therapy for Parkinson's disease (PD), and elezanumab, a monoclonal antibody directed against repulsive guidance molecule A (RGMa) in multiple sclerosis (MS), among other data to be presented

AbbVie Climbs Earnings Beat, Guidance Boost

AbbVie Climbs Earnings Beat, Guidance Boost

AbbVie climbs after beating first-quarter estimates and raising full-year guidance.

Earnings, Earnings and More Earnings, Facebook Results: Market Recon

Earnings, Earnings and More Earnings, Facebook Results: Market Recon

As we have seen so far, in terms of market reaction, there is great reward at the point of sale in beating expectations.

AbbVie Reports First-Quarter 2019 Financial Results

AbbVie Reports First-Quarter 2019 Financial Results

- Reports First-Quarter Diluted EPS of $1.65 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 14.4 Percent

TheStreet Quant Rating: C (Hold)